Suppression of the nuclear factor-κB activation pathway by spice-derived phytochemicals: Reasoning for seasoning

Annals of the New York Academy of Sciences

Volumn 1030, Issue , 2004, Pages 434-441

  Aggarwal, Bharat B ^a   Shishodia, Shishir ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inflammation; NF B; TNF

Indexed keywords

ACETYLSALICYLIC ACID; AJOENE; ALLYL SULFIDE; ANETHOLE; ANISE OIL; ANTINEOPLASTIC AGENT; CAPSAICIN; CLOVE OIL; CURCUMIN; EUGENOL; FLAVONOID; FOENICULUM VULGARE EXTRACT; GARLIC EXTRACT; GINGER EXTRACT; GINGEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOEUGENOL; OCIMUM BASILICUM EXTRACT; PLANT EXTRACT; PUNICA GRANATUM EXTRACT; URSOLIC ACID;

ALZHEIMER DISEASE; ANISE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BASIL; CANCER; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLOVE; CONFERENCE PAPER; CROHN DISEASE; CUMIN; CURCUMA LONGA; FENNEL; GARLIC; GASTROINTESTINAL DISEASE; GINGER; HEADACHE; HEART INFARCTION; HUMAN; NAUSEA; NONHUMAN; PAIN; PEPPER; PHYTOCHEMISTRY; POMEGRANATE; PSORIASIS; ROSEMARY; SIDE EFFECT; SPICE; TRANSCRIPTION INITIATION;

ALLIUM SATIVUM; CAPSICUM ANNUUM VAR. ANNUUM; CUMINUM CYMINUM; CURCUMA LONGA; FOENICULUM VULGARE; LYTHRACEAE; MYRRHIS ODORATA; OCIMUM BASILICUM; ROSMARINUS OFFICINALIS; ZINGIBER OFFICINALE;

EID: 15044361086     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1329.054     Document Type: Conference Paper

References (56)

1. GARG, A. & B.B. AGGARWAL. 2002. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 16: 1053-1068.
2. KUMAR, A., Y. TAKADA, A.M. BORIEK & B.B. AGGARWAL. 2004. Nuclear factor-κB: its role in health and diseases. J. Mol. Med. 82: 434-448.
3. SHISHODIA, S. & B.B. AGGARWAL. 2004. Nuclear factor (NF)-κB regulates the expression of genes involved in transformation, proliferation, invasion, angiogenesis and metastasis of cancer. Cancer Treat. Res. 119: 139-173.
4. LIN, A. & M. KARIN. 2003. NF-κB in cancer: a marked target. Semin. Cancer Biol. 13: 107-114.
5. ORLOWSKI, R.Z. & A.S. BALDWIN, JR. 2002. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 8: 385-389.
6. VALEN, G., Z.Q. YAN & G.K. HANSSON. 2001. Nuclear factor κ-B and the heart. J. Am. Coll. Cardiol. 38: 307-314.
7. JONES, W.K., M. BROWN, X. REN, et al. 2003. NF-κB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc. Toxicol. 3: 229-254.
8. SHOELSON, S.E., J. LEE & M. YUAN. 2003. Inflammation and the IKK β/1 κ B/NF-κ B axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 27(Suppl. 3): S49-S52.
9. YANG, L., L. COHN, D.H. ZHANG, et al. 1998. Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med. 188: 1739-1750.
10. DAS, J., C.H. CHEN, L. YANG, et al. 2001. A critical role for NF-κB in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2: 45-50.
11. GAGLIARDO, R., P. CHANEZ, M. MATHIEU, et al. 2003. Persistent activation of nuclear factor-κB signaling pathway in severe uncontrolled asthma. Am. J. Respir. Crit. Care Med. 168: 1190-1198.
12. ROSHAK, A.K., J.F. CALLAHAN & S.M. BLAKE. 2002. Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease. Curr. Opin. Pharmacol. 2: 316-321.
13. VAN HEEL, D.A., I.A. UDALOVA, A.P. DESILVA, et al. 2002. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum. Mol. Genet. 11: 1281-1289.
14. HUANG, C.J., R. NAZARIAN, J. LEE, et al. 2002. Tumor necrosis factor modulates transcription of myelin basic protein gene through nuclear factor κB in a human oligodendroglioma cell line. Int. J. Dev. Neurosci. 20: 289-296,
15. MATTSON, M.P. & S. CAMANDOLA. 2001. NF-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107: 247-254.
16. KALTSCHMIDT, B., M. UHEREK, B. VOLK, et al. 1997. Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 94: 2642-2647.
17. BURKE, J.R. 2003. Targeting I κ B kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Dev. 6: 720-728.
18. YAMAMOTO, Y. & R.B. GAYNOR. 2001. Role of the NF-κB pathway in the pathogenesis of human disease states. Curr. Mol. Med. 1: 287-296.
19. YAMAMOTO, Y. & R.B. GAYNOR. 2001. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107: 135-142.
20. GORMAN, C. & A. PARK. 2004. The fires within. Time February 23. 163(8): 42-46.
21. SHOBANA, S. & K.A. NAIDU. 2000. Antioxidant activity of selected Indian spices. Prostaglandins Leukot. Essent. Fatty Acids 62: 107-110.
22. AGGARWAL, B.B., A. KUMAR & A.C. BHARTI. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23: 363-398.
23. SINGH, S. & B.B. AGGARWAL. 1995. Activation of transcription factor NF-κ B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270: 24995-25000.
24. BHARTI, A.C., N. DONATO, S. SINGH & B.B. AGGARWAL. 2003. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κ B and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062.
25. MUKHOPADHYAY, A., S. BANERJEE, L.J. STAFFORD, et al. 2002. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21: 8852-8861.
26. MUKHOPADHYAY, A., C. BUESO-RAMOS, D. CHATTERJEE, et al. 2001. Curcumin down-regulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 7597-7609.
27. MEHTA, K., P. PANTAZIS, T. MCQUEEN & B.B. AGGARWAL. 1997. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8: 470-481.
28. ANTO, R.J., A. MUKHOPADHYAY, K. DENNING & B.B. AGGARWAL. 2002. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23: 143-150.
29. BHARTI, A.C., S. SHISHODIA, J.M. REUBEN, et al. 2003. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184.
30. BHARTI, A.C., Y. TAKADA & B.B. AGGARWAL. 2004. Curcumin (diferuloylmethane) inhibits RANK ligand-induced NF-κ B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol. 172: 5940-5947.
31. SHISHODIA, S., P. POTDAR, C.G. GAIROLA & B.B. AGGARWAL. 2003. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24: 1269-1279.
32. KUMAR, A., S. DHAWAN, N.J. HARDEGEN & B.B. AGGARWAL. 1998. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochem. Pharmacol. 55: 775-783.
33. REDDY, S. & B.B. AGGARWAL. 1994. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett. 341: 19-22.
34. AGGARWAL, B.B., A. KUMAR, M.S. AGGARWAL & S. SHISHODIA. 2004. Curcumin derived from turmeric (Curcuma longa): a spice for all seasons. In Phytochemicals in Cancer Chemoprevention. D. Bagchi & H.G. Preuss, Eds.: 349-387. CRC Press. Boca Raton, FL.
35. HAIL, N., JR. & R. LOTAN. 2002. Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J. Natl. Cancer Inst. 94: 1281-1292.
36. SURH, YJ.. 2002. More than spice: capsaicin in hot chili peppers makes tumor cells commit suicide. J. Natl. Cancer Inst. 94: 1263-1265.
37. SINGH, S., K. NATARAJAN & B.B. AGGARWAL. 1996. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-κ B activation by diverse agents. J. Immunol. 157: 4412-4420.
38. RUBERTO, G., M.T. BARATTA, S.G. DEANS & H.J. DORMAN. 2000. Antioxidant and antimicrobial activity of Foeniculum vulgare and Crithmum maritimum essential oils. Planta Med. 66: 687-693.
39. ALBERT-PULEO, M. 1980. Fennel and anise as estrogenic agents. J. Ethnopharmacol. 2: 337-344.
40. SEN, C.K., K.E. TRABER & L. PACKER. 1996. Inhibition of NF-κ B activation in human T-cell lines by anetholdithiolthione. Biochem. Biophys. Res. Commun. 218: 148-153.
41. CHAINY, G.B., S.K. MANNA, M.M. CHATURVEDI & B.B. AGGARWAL. 2000. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-κB, AP-1, JNK, MAPKK and apoptosis. Oncogene 19: 2943-2950.
42. MURAKAMI, Y., M. SHOJI, S. HANAZAWA, et al. 2003. Preventive effect of bis-eugenol, a eugenol ortho dimer, on lipopolysaccharide-stimulated nuclear factor κ B activation and inflammatory cytokine expression in macrophages. Biochem. Pharmacol. 66: 1061-1066.
43. YAMAHARA, J., H.Q. RONG, Y. NAITOH, et al. 1989. Inhibition of cytotoxic drug-induced vomiting in suncus by a ginger constituent. J. Ethnopharmacol. 27: 353-355.
44. YAMAHARA, J., M. MOCHIZUKI, H.Q. RONG, et al. 1988. The anti-ulcer effect in rats of ginger constituents. J. Ethnopharmacol. 23: 299-304.
45. BODE, A.M., W.Y. MA, Y.J. SURH & Z. DONG. 2001. Inhibition of epidermal growth factor-induced cell transformation and activator protein 1 activation by [6]-gingerol. Cancer Res. 61: 850-853.
46. TJENDRAPUTRA, E., V.H. TRAN, D. LIU-BRENNAN, et al. 2001. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorg. Chem. 29: 156-163.
47. KOO, K.L., A.J. AMMIT, V.H. TRAN, et al. 2001. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thromb. Res. 103: 387-397.
48. SHISHODIA, S., S. MAJUMDAR, S. BANERJEE & B.B. AGGARWAL. 2003. Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 63: 4375-4383.
49. DIRSCH, V.M., D.S. ANTLSPERGER, H. HENTZE & A.M. VOLLMAR. 2002. Ajoene, an experimental anti-leukemic drug: mechanism of cell death. Leukemia 16: 74-83.
50. GENG, Z., Y. RONG & B.H. LAU. 1997. S-Allyl cysteine inhibits activation of nuclear factor κ B in human T cells. Free Radic. Biol. Med. 23: 345-350.
51. IDE, N. & B.H. LAU. 2001. Garlic compounds minimize intracellular oxidative stress and inhibit nuclear factor-κ B activation. J. Nutr. 131: 1020S-1026S.
52. KEISS, H.P., V.M. DIRSCH, T. HARTUNG, et al. 2003. Garlic (Allium sativum L.) modulates cytokine expression in lipopolysaccharide-activated human blood thereby inhibiting NF-κB activity. J. Nutr. 133: 2171-2175.
53. AVIRAM, M., L. DORNFELD, M. KAPLAN, et al. 2002. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp. Clin. Res. 28: 49-62.
54. AVIRAM, M. & L. DORNFELD. 2001. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 158: 195-198.
55. SCHUBERT, S.Y., I. NEEMAN & N. RESNICK. 2002. A novel mechanism for the inhibition of NF-κB activation in vascular endothelial cells by natural antioxidants. FASEB J. 16: 1931-1933.
56. SURH, Y.J. 2002. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem. Toxicol. 40: 1091-1097.